People in the News

Premium

Frank Witney has been named chief commercial officer at Affymetrix. As CCO, Witney is charged with integrating the commercial teams of Affy and its recently acquired companies, Panomics, True Materials, and USB.

Witney joined Panomics, formerly Genospectra, as CEO in 2002. Prior to that, he served as president of drug discovery tools at PerkinElmer Life sciences.

Witney was a postdoc fellow at the National Institutes of Health and holds a PhD in molecular and cell biology from Indiana University.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.